INS and obesity disorder: GIP and GLP-1 dual agonists, such as Mounjaro, enable insulin secretion through activation of β-cell GIP receptors and appear to greatly enhance the satiety and weight loss encountered with GLP-1R activation alone, aiding obesity [129,130].